Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merz Pharmaceuticals said that the Centers for Medicare and Medicaid Services (CMS) has assigned a product-specific Healthcare Common Procedure Coding System (HCPCS) billing code, J0588 'Injection, incobotulinumtoxin a, 1 unit' for Xeomin (incobotulinumtoxinA).
Subscribe to our email newsletter
Xeomin was approved by the US FDA in July 2010 for the treatment of cervical dystonia in adults.
The drug is believed to decrease the severity of abnormal head position and neck pain in both botulinum toxin-naive and previously treated patients, and blepharospasm in adults who have been previously treated with Botox (onabotulinumtoxinA).
Xeomin is type A botulinum neurotoxin that is available in 50-unit single use vials that may allow for a reduction in wastage and may minimize patient out-of-pocket expenses, the company said.
Dystonia Medical Research Foundation (DMRF) Executive Director Janet Hieshetter said the company is happy to have been granted a permanent product-specific code for Xeomin.
"This milestone reinforces the importance of ensuring access to all available treatment options. The DMRF congratulates Merz on this achievement and applauds their ongoing dedication to patient and physician support," Hieshetter added.